Niclosamide
Catalog No.S3030 Synonyms: Niclocide
Molecular Weight(MW): 327.12
Niclosamide can inhibit DNA replication and inhibit STAT3 with IC50 of 0.7 μM in a cell-free assay. Niclosamide selectively inhibited the phosphorylation of STAT3 and had no obvious inhibition against the activation of other homologues (e.g., STAT1 and STAT5).
6 Customer Reviews
-
Effects of some confirmed hits on IRF7 transcription level in response to IFN-α2a treatment (1 h) in SH-SY5Y cells. Data represent mean expression fold±SEM relative to GAPDH, measured from three independent experiments, each in triplicates. *P<0.05, **P<0.01, and ***P<0.001 compared to IFN-α2a treated cells.
Acta Pharm Sin B, 2018, 8(6):889-899. Niclosamide purchased from Selleck.
(B) H&E images. (C–E) IHC for PCNA, pSTAT3, and pPI3K after the drug treatment. BKM120 treatment showed downregulation of the pPI3K expression. pSTAT3 expression, however, was not completely suppressed by STAT3 inhibitor treatment. Note that pSTAT3 and PCNA were heavily expressed in the same dysplastic area of serial sections (red circles, sections from the same liver tissue). (F) ISH for Appa showing downregulation by STAT3 inhibitors. Bars, 50 μm.
Neoplasia, 2015, 17(7):586-97. Niclosamide purchased from Selleck.
-
LAMP1 IF analysis. (A) Representative confocal IF images (60×) of LAMP1 (green) in SK-GT-4 cells or (C) FLO-1 cells treated with vehicle or niclosamide (0.5 μM) for 48 hours. Arrows point to cells with peripheral lysosomes, while arrowheads indicate cells with perinuclear lysosomes. (B) Quantification of the percentage of SK-GT-4 cells or (D) FLO-1 cells with either peripheral or perinuclear lysosomes relative to their respective total cell number after treatment with vehicle or niclosamide.
Neoplasia, 2018, 20(10):1008-1022. Niclosamide purchased from Selleck.
Bacterial infection in IPEC-J2 cells. The invasion and attachment of EHECO157:H7 was increased in the IPEC-J2 cells in the presence of 1 μM niclosamide. Data are expressed as the mean ± SEM (n= 6). Differences between groups were determined by paired samples t-test. *P<0.05 compared with the control.
Int Immunopharmacol, 2016, 36:199-204.. Niclosamide purchased from Selleck.
-
Inhibition of STAT3 phosphorylation by niclosamide in colon cancer cells HCT116 and SW620. Notes: (A) SW620 cells were treated with niclosamide (5 µM) for different lengths of time (0, 2, 4, 6, 8, and 12 h). Total protein was extracted, and the expression levels of P-STAT3, STAT3, and GAPDH proteins were detected by Western blot analysis. (B) HCT116 cells were treated with niclosamide (5 µM) for different lengths of time (0, 2, 4, 6, 8, and 12 h). Total protein was extracted, and the expression levels of P-STAT3, STAT3, and GAPDH proteins were detected by Western blot analysis. (C) SW620 cells were treated with niclosamide at different concentrations (0.5, 1, 2.5, 5, and 10 µM) or vehicle control (DMSO) for 12 h. (D) HCT116 cells were treated with niclosamide at different concentrations (0.5, 1, 2.5, 5, and 10 µM) or vehicle control (DMSO) for 12 h. Total protein was then extracted and detected by Western blot analysis. The data were obtained from 3 independent experiments. *P<0.05.
Onco Targets Ther, 2017, 10:1767-1776. Niclosamide purchased from Selleck.
STAT 3 inhibitor, niclosamide, had the antitumor activity for ovarian clear cell cancer cell lines, KK. (A) Niclosamide had antitumor effect for ovarian clear-cell carcinoma cell line, KK. (B) Western blot analysis revealed the downregulation of p-STAT3, and XIAP proteins and increased expression of cleaved-PARP by treatment with niclosamide in a dose-dependent manner. Cell viability was assessed using MTT assay after 24 h from the treatment with niclosamide. Equivalent amounts (10 µg) of protein were subjected to SDS-PAGE and blotted with anti-STAT3, anti-phospho-STAT3, anti-XIAP, anti-cleaved-PARP, and anti-β-actin antibodies.
Oncol Lett, 2018, 15(4):5772-5780. Niclosamide purchased from Selleck.
Purity & Quality Control
Choose Selective STAT Inhibitors
Biological Activity
| Description | Niclosamide can inhibit DNA replication and inhibit STAT3 with IC50 of 0.7 μM in a cell-free assay. Niclosamide selectively inhibited the phosphorylation of STAT3 and had no obvious inhibition against the activation of other homologues (e.g., STAT1 and STAT5). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Targets |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In vitro |
Niclosamide (< 5 μM) dose dependently inhibits STAT3-mediated luciferase reporter activity with IC50 of 0.25 μM in HeLa cells. Niclosamide(< 2 μM) dose dependently inhibits the phosphorylation of STAT3 in Du145 cells. Niclosamide (1 μM) inhibits the EGF-induced nuclear translocation of STAT3 in Du145 cells. Niclosamide(< 2 μM) dose dependently inhibits the transcription of STAT3 downstream genes in Du145 cells. Niclosamide(< 10 μM) dose dependently induces G0/G1 arrest and apoptosis of Du145 cancer cells. [1] Niclosamide is able to inhibit SARS-CoV replication at a micromolar concentration in Vero E6 cells infected with SARS-CoV. [2] Niclosamide(< 7.5 μM) promotes Frizzled1 endocytosis, downregulates Dishevelled-2 protein, and inhibits Wnt3A-stimulated beta-catenin stabilization and LEF/TCF reporter activity in U2OS cells. [3] Niclosamide inhibits the TNF-induced NF-κB reporter activity in a dose- and time-dependent manner in U2OS cells. Niclosamide(125 nM) inhibits NF-κB activation induced by p65, IKKα, IKKβ, IKKγ, and TAK1 in U2OS cells. Niclosamide(< 500 nM) completely block the time- and dose-dependent TNFα-induced alteration of the NF-κB–DNA complex in HL-60 cells. Niclosamide(< 10 nM) inhibits constitutive NF-κB activation in U266 cells. Niclosamide inhibits TNF-induced degradation of IκBα and relocation of p65 in a dose- and time-dependent manner in HL-60, Molm13, or AML primary cells. Niclosamide(500 nM) decreases TNF-induced NF-κB–dependent gene products involved in cell survival in HL-60 cells. Niclosamide dose dependently inhibits the growth and induces robust apoptosis of AML cells associated with decreased Mcl-1 and XIAP levels and increased intracellular ROS levels. [4] |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cell Data |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| In vivo | Niclosamide(40 mg/kg/d, i.p.) inhibits growth of xenografted AML cells in nude mice bearing HL-60 xenograft tumors. [4] |
Protocol
| Kinase Assay: |
+ Expand
Protein Kinase profiling assay: Assay for 22 different proteins kinases is carried out by ProQinase Gmbh. All of the protein kinases are expressed either in Sf9 insect cells or in E.coli as recombinant GST-fusion proteins or His-tagged proteins. Protein kinases are purified by affinity chromatography using either GSH-agarose or Ni_NTH-agarose. A radiometric protein kinase assay is used for measuring the kinase activity of the 22 protein kinases. Briefly, for each protein kinase, 50 μL reaction cocktail containing 60 mM HEPES-NaOH, 3 mM MgCl2, 3 mM MnCl2, 3 μM Na-orthovanadate, 1.2 mM DTT, 50 μg/mL PEG20000, 1 μM [γ-33P]-ATP, Niclosamide, adequate amount of enzyme and its substrate. The PKC-alpha assay additionally contain 1 mM Cacl2, 4 mM EDTA, 5 μg/mL phosphatidylserine and 1 μg/mL 1, 2-Dioleyl-glycerol. The reaction cocktails are incubated at 37 °C for 60 minutes and stop with 50 μL 2% (v/v) H3PO4. Incorporation of 33Pi is determined with a microplate scintillation counter. The activities and the IC50 values are calculated using Quattro Workflow V2.28. |
|---|---|
| Cell Research: |
+ Expand
|
| Animal Research: |
+ Expand
|
Solubility (25°C)
| In vitro | DMF | 12 mg/mL warmed (36.68 mM) |
|---|---|---|
| DMSO | Insoluble | |
| Water | Insoluble | |
| In vivo | Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing. |
30 mg/mL |
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Information
| Molecular Weight | 327.12 |
|---|---|
| Formula | C13H8Cl2N2O4 |
| CAS No. | 50-65-7 |
| Storage | powder |
| in solvent | |
| Synonyms | Niclocide |
Bio Calculators
Molarity Calculator
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Dilution Calculator
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Molarity Calculator
Clinical Trial Information
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03521232 | Recruiting | Ulcerative Colitis|Ulcerative Proctitis|Ulcerative Proctosigmoiditis | First Wave Bio Inc. | May 15 2018 | Phase 1|Phase 2 |
| NCT03521232 | Recruiting | Ulcerative Colitis|Ulcerative Proctitis|Ulcerative Proctosigmoiditis | First Wave Bio Inc. | May 15 2018 | Phase 1|Phase 2 |
| NCT02687009 | Recruiting | Colon Cancer | Michael Morse MD|Duke University | November 7 2017 | Phase 1 |
| NCT02687009 | Recruiting | Colon Cancer | Michael Morse MD|Duke University | November 7 2017 | Phase 1 |
| NCT03160001 | Completed | Rheumatoid Arthritis (RA) | Faiq Gorial|University of Baghdad | August 15 2017 | Phase 1|Phase 2 |
| NCT03160001 | Completed | Rheumatoid Arthritis (RA) | Faiq Gorial|University of Baghdad | August 15 2017 | Phase 1|Phase 2 |
Tech Support
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
